
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

Jolt Capital boosts BC Platforms with $20m
Espoo-based BC Platforms, an international healthcare data provider and software developer, in November has baged an investment of $20m from the...

Step Pharma presents promising cancer treatment
Since September 2022, STP938, the cancer inhibitor developed by Step Pharma SAS, has been undergoing clinical trials for the treatment of T and B...

Novadip Biosciences SA raises €40m
Belgian regenerative medicine specialist Novadip Biosciences has raised €40m to push clinical development of its two investigational adipose stem...

Hummingbird and Synaffix in $150m ADC deal
Under the deal, Synaffix can earn up to $150m, including upfront and milestone payments, plus royalties on net sales if the ADC resulting from the...

Fungal skin replaces plastics in electronics
In a proof-of-concept study, Doris Danninger and colleagues demonstrate that fungal mycelium skins can be grown and processed to serve as substrates...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...